Generics-Makers Tell 3rd Circ. Buyers Too Few For Class
Two pharmaceutical companies embroiled in decade-long litigation over the alleged price-fixing of generic drugs told a Third Circuit panel on Tuesday that groups of drug buyers either didn't have the numbers...To view the full article, register now.
Already a subscriber? Click here to view full article